Eversense 365 and SweetSpot Integrate Software to Optimize Diabetes Care
Senseonics and Ascensia integrate software between SweetSpot and Eversense 365, the world's first and only One Year CGM system
SweetSpot partners with endocrinology practices to provide virtual CGM monitoring and enhanced patient care
GERMANTOWN, Md. and PARSIPPANY, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE: SENS) and Ascensia Diabetes Care announce the software integration of SweetSpot™ with the Eversense® 365 Continuous Glucose Monitoring (CGM) System in the U.S. This software integration provides endocrinology practices that partner with SweetSpot the ability to continue to improve patient care by seamlessly and regularly reviewing data from patients using Eversense 365, the world's first and only One Year CGM.
SweetSpot combines a centralized software platform for managing diabetes device data with wrap-around clinical support services. SweetSpot's virtual team of Certified Diabetes Care and Education Specialists (CDCES) perform monthly CGM data reviews and coordinate with providers and patients on treatment plan assessment and changes. By developing an integration with Eversense 365, SweetSpot can work alongside practices to act on this unique system's CGM data in between patients' scheduled appointments, allowing for more personalized support. These regular data reviews help ensure patients get timely treatment adjustments, keeping them better connected to their diabetes care team year-round with a goal of improving glycemic control. Practices can also unlock new opportunities through SweetSpot's automated capture of reimbursable care events, making partnering with SweetSpot both clinically impactful and operationally efficient.
Eversense 365 is developed by Senseonics and brought to patients by Ascensia Diabetes Care, a subsidiary of PHC Holdings Corporation (TSE: 6523). As the only implantable CGM available, it offers patients a truly differentiated CGM experience, providing One Year of exceptionally accurate monitoring with minimal interruptions. It benefits endocrinologists and care teams by offering their patients confidence in decision-making, long-term peace of mind and enhanced quality of life with just one CGM. The unique approach also allows people to overcome common frustrations and interruptions experienced with traditional, short-term CGMs, so that patients can focus on managing their diabetes and not their CGM.
Dr Ralph Oiknine, Physician, Co-Founder and Chief Medical Officer of SweetSpot, said: 'SweetSpot removes all the barriers to implementing a strong, virtual CGM monitoring program for endocrinology practices and all providers involved in diabetes care. Our dedicated team is passionate about transforming how diabetes is managed – and making sure that no opportunities are missed to use the rich data from CGMs for improved care. This integration with Eversense reinforces SweetSpot's commitment to seamless diabetes management, driving better patient outcomes and practice growth for our partners by integrating more CGM options, such as the only implantable CGM on the market.'
Mukul Jain, Chief Operating Officer of Senseonics, added: 'We are pleased to enable integration with SweetSpot to help healthcare providers using the software platform to optimize care for patients using Eversense 365. Our CGM offers a completely fresh approach to diabetes management by collecting a whole year of glucose data with just one CGM. We continue to focus on bringing Eversense 365 to more people across the country and are excited to see how integrations like this can further enhance our compelling offering for patients and healthcare providers.'
Dr. Jacob Vadakekalam of the Diabetes & Glandular Disease (DGD) Clinic in San Antonio, Texas, added: 'As a doctor committed to providing the best care possible, I am pleased about the partnership between SweetSpot and Eversense. This collaboration represents a step forward in healthcare integration, and I believe it will have a positive impact on diabetes management for my patients here at the Diabetes & Glandular Disease Clinic and in turn minimizing future hospitalizations.'
Notes for Editors
About Eversense
The Eversense® Continuous Glucose Monitoring (CGM) Systems are indicated for continually measuring glucose levels for up to 365 days for Eversense® 365 and 180 days for Eversense® E3 in persons with diabetes age 18 and older. The systems are indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time per week after day 13 for Eversense® 365 and one time per day after day 21 for Eversense® E3, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense CGM Systems are prescription devices; patients should talk to their health care provider to learn more. For important safety information, see www.eversensediabetes.com/safety-info/.
A media kit for Eversense 365, including images, logos and further information, can be accessed at www.ascensia.com/media/eversense365-media-kit/
About SweetSpot
SweetSpot partners with endocrinology practices to provide virtual CGM monitoring and enhanced patient care. SweetSpot combines a centralized software platform for managing diabetes device data, such as data from CGMs and insulin pumps, with wrap-around clinical support services. SweetSpot's virtual team of Certified Diabetes Care and Education Specialists (CDCES) perform monthly CGM data reviews and coordinate with providers and patients to facilitate treatment plan changes. By actively managing and remotely reviewing CGM data between patient visits, we ensure patients receive timely treatment adjustments to improve glycemic control and patient outcomes. Additionally, SweetSpot's automated capture of reimbursable care events optimizes CPT code utilization, unlocking new revenue streams for practices and making our partnerships both clinically effective and financially profitable.For more information, visit www.sweetspot.health.
About Senseonics
Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM system Eversense® 365 includes a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.
About Ascensia Diabetes Care
Ascensia Diabetes Care is a global company focused entirely on helping people with diabetes. Our mission is to empower those living with diabetes through innovative solutions that simplify and improve their lives.
We are home to the world-renowned CONTOUR® portfolio of blood glucose monitoring systems and the exclusive global distribution partner for the Eversense® Continuous Glucose Monitoring Systems from Senseonics. These products combine advanced technology with user-friendly functionality to help people with diabetes manage their condition and make a positive difference to their lives. As a trusted partner in the diabetes community, we collaborate closely with healthcare professionals and other partners to ensure our products meet the highest standards of accuracy, precision and reliability, and that we conduct our business compliantly and with integrity.
Ascensia is a member of PHC Group and was established in 2016 through the acquisition of Bayer Diabetes Care by PHC Holdings Corporation. Ascensia products are sold in more than 100 countries. Ascensia has around 1,400 employees and operations in 29 countries. For further information, please visit the Ascensia Diabetes Care website at: www.ascensia.com
About PHC Holdings Corporation
PHC Holdings Corporation (TSE 6523) is a global healthcare company with a mission of contributing to the health of society through healthcare solutions that have a positive impact and improve the lives of people. Its subsidiaries (referred to collectively as PHC Group) include PHC Corporation, Ascensia Diabetes Care Holdings AG, Epredia Holdings Ltd., LSI Medience Corporation, Mediford Corporation, and Wemex. Together, these companies develop, manufacture, sell and service solutions across diabetes management, healthcare solutions, life sciences and diagnostics. PHC Group's consolidated net sales in FY2023 were JPY 353.9 billion with global distribution of products and services in more than 125 countries.
www.phchd.com
Forward Looking Statements
Any statements in this press release about the expectations regarding potential impact on patients' and providers' experience and outcomes, and other statements containing the words "believe," 'expect,' 'intend,' 'may,' 'projects,' 'will,' 'planned,' and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties inherent in the new product launch and ongoing commercialization of Eversense 365, uncertainties inherent in the coordination with third parties and new partners, uncertainties in prescriber and patient decisions and responses to new technology or initiatives, and such other factors as are set forth in the risk factors detailed in Senseonics' Annual Report on Form 10-K for the year ended December 31, 2023 and subsequent quarterly reports on Form 10-Q filed with the SEC under the heading "Risk Factors." In addition, the forward-looking statements included in this press release represent Senseonics' views as of the date hereof. Senseonics anticipates that subsequent events and developments will cause Senseonics' views to change. However, while Senseonics may elect to update these forward-looking statements at some point in the future, Senseonics specifically disclaims any obligation to do so except as required by law. These forward-looking statements should not be relied upon as representing Senseonics' views as of any date subsequent to the date hereof.
Ascensia Communications Contact:
Tim StamperFTI ConsultingTim.Stamper@fticonsulting.com
Senseonics Investor Contact
Jeremy FefferLifeSci Advisorsinvestors@senseonics.com
SweetSpot Communications Contact:
Joelle FredmanDirector of Marketingjfredman@aegisdigitalhealth.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Lemonade Inc (LMND) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Challenges
Revenue: Increased 27% year-on-year to $151 million in Q1 2025. In Force Premium (IFP): Grew 27% to just above $1 billion. Customer Count: Increased by 21% to 2.5 million. Premium per Customer: Increased 4% to $396. Annual Retention Rate (ADR): Decreased to 84% from 86% in the prior quarter. Gross Earned Premium: Increased 24% to $234 million. Gross Loss Ratio: 78% for Q1, compared to 79% in Q1 2024. Adjusted Gross Profit: Improved 25% year-on-year. Net Loss: $62 million, or a loss of $0.86 per share. Adjusted EBITDA Loss: $47 million in Q1. Total Cash, Cash Equivalents, and Investments: Approximately $996 million. Growth Spend: $38 million in Q1, nearly double the prior year quarter. Technology Development Expense: Increased 5% to $22 million. General and Administrative (G&A) Expense: Increased 20% to $36 million. Warning! GuruFocus has detected 3 Warning Signs with LMND. Release Date: May 06, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Lemonade Inc (NYSE:LMND) reported a 27% year-on-year growth in Q1 2025, marking the sixth consecutive quarter of accelerating top-line growth. The company achieved a 25% year-on-year improvement in adjusted gross profit, despite the impact of California wildfires. Lemonade Car's quarter-over-quarter in-force premium (IFP) growth outpaced the rest of the business for the first time, signaling strong momentum. The company is on track to achieve EBITDA breakeven by the end of 2026, with expectations of generating positive adjusted free cash flow in 2025. Lemonade Inc (NYSE:LMND) has successfully leveraged AI to maintain or reduce fixed costs while significantly increasing its book size, demonstrating strong operational efficiency. The California wildfires had a notable impact on Q1 results, contributing 16 percentage points to the gross loss ratio. Annual dollar retention (ADR) decreased to 84%, down from 86% in the prior quarter, partly due to efforts to improve profitability in the home insurance book. The gross loss ratio for Q1 was 78%, slightly higher than the previous year's 79%, indicating ongoing challenges in managing claims costs. Operating expenses, excluding loss and loss adjustment expense, increased by 29% year-on-year, driven by growth spend and the impact of the FAIR plan assessment. Net loss for Q1 was $62 million, or $0.86 per share, compared to a net loss of $47 million or $0.67 per share in the prior year, reflecting ongoing financial challenges. Q: Can you elaborate on the timeline for reaching EBITDA profitability and what levers will drive this? A: Daniel Schreiber, CEO, explained that Lemonade aims to achieve adjusted EBITDA breakeven by the end of 2026, with 2027 being the first full year of positive adjusted EBITDA. The company expects gross profit to grow faster than fixed costs, driven by AI efficiencies, bringing them closer to profitability. Q: What impact did the California wildfires have on gross profit, and how are tariffs affecting your full-year guidance? A: Tim Bixby, CFO, noted that the California wildfires had a $44 million gross impact, aligning with prior estimates. The tariff impact is expected to be modest, with single-digit percentage effects on claims. Lemonade is comfortable with its full-year guidance, assuming a modest headwind from tariffs. Q: How is Lemonade's Car business performing, and what are the plans for geographic expansion? A: Daniel Schreiber, CEO, highlighted that Lemonade Car is growing faster than the rest of the business, with a focus on refining the product before expanding geographically. The company is currently available to 40% of the U.S. market and plans to expand further once the product is optimized. Q: How is AI impacting Lemonade's competitive position in the insurance industry? A: Daniel Schreiber, CEO, emphasized that Lemonade's AI capabilities allow for better data utilization and risk assessment compared to traditional insurers. The company's digital infrastructure enables it to connect data points effectively, providing a competitive advantage in pricing and customer acquisition. Q: What percentage of new car sales are cross-sales from existing Lemonade customers? A: Tim Bixby, CFO, stated that about half of new car sales are cross-sales from existing customers, up from a third previously. This trend is expected to continue, leveraging Lemonade's existing customer base for more efficient growth. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Business Insider
an hour ago
- Business Insider
CEG, OKLO, and SMR Get Set to Power the AI Boom via Nuclear Energy
The nuclear energy sector is experiencing a resurgence unseen in decades, driven largely by its potential to power the burgeoning AI revolution. Major technology companies such as Meta (META), Microsoft (MSFT), and Alphabet (GOOGL) are competing to secure reliable energy sources for their expanding data centers, and nuclear power's clean, consistent output has positioned it as a key player in this race. Confident Investing Starts Here: Leading this revival are three companies—Constellation Energy (CEG), Oklo (OKLO), and NuScale Power (SMR) —each bringing a distinct approach to the nuclear landscape. Over the past year, all three have outperformed the market, capturing investor attention amid rising energy demand. Constellation Energy (NASDAQ:CEG) | The Nuclear Titan Locking in Tech Giants Constellation Energy is the 800-pound gorilla of U.S. nuclear power, and it's just landed a deal that's got everyone's attention. Just two days ago, CEG signed a 20-year power purchase agreement with Meta to deliver 1.1 gigawatts from its Clinton Clean Energy Center in Illinois, starting in 2027. This isn't an ordinary contract, but rather a lifeline for a plant that was on the verge of closure when its zero-emissions credits expire. The deal, which also boosts Clinton's output by 30 megawatts, underscores CEG's ability to secure tech giants. Microsoft is already on board with a Three Mile Island restart. What makes CEG a one-of-a-kind destination for tech titans is its scale. With 94 reactors across the U.S., they're a one-stop shop for tech companies chasing net-zero goals while powering AI workloads. Their shift away from co-located data center plans to grid-connected projects, as noted in last month's update, indicates they're adapting to regulatory hurdles, such as FERC's rejection of expanded co-location deals. Moreover, the Meta deal demonstrates that CEG can pivot and still secure massive contracts. Sure, their stock's run-up makes it a bit daunting to be bullish on today, but with AI data centers projected to eat up 9% of U.S. electricity by 2030, CEG's infrastructure could be a cash cow in waiting. Is Constellation Energy Stock a Good Buy? Currently, most analysts are bullish on CEG stock. The stock features a Moderate Buy consensus rating based on eight Buy and five Hold ratings assigned in the past three months. No analyst rates the stock a sell. CEG's average stock price target of $319.45 implies ~10% upside over the next twelve months, despite shares having already rallied 30% year-to-date. Oklo (NYSE:OKLO) | The Startup with a Nuclear Vision Oklo, the newest entrant in the nuclear energy space and backed by OpenAI's Sam Altman, is focused on small modular reactors (SMRs)—compact, flexible power plants ideally suited for data centers. The company's stock has surged 440% over the past year, fueled by high-profile agreements such as its December deal with Switch to supply 12 gigawatts through 2044. Additionally, a recent memorandum with Korea Hydro & Nuclear Power to advance their 75-megawatt Aurora Powerhouse fast reactor has further accelerated momentum. While Oklo remains pre-revenue and is currently investing heavily in technology development, with commercial operations still several years away, its 'power-as-a-service' model—where the company builds, owns, and operates reactors—could revolutionize how data centers secure reliable power without significant upfront costs. Recent executive orders easing nuclear regulations have also provided a regulatory boost. However, significant risks remain, including ongoing R&D challenges and the high costs of scaling production. For investors who believe SMRs are key to powering the AI revolution, Oklo's long-term vision holds considerable promise. Is OKLO Stock a Good Buy? On Wall Street, Oklo stock carries a Moderate Buy consensus rating based on six Buy and three Hold ratings. No analyst rates the stock a sell. Oklo's average stock price target of $54.40 implies about 15% upside potential over the next twelve months. NuScale Power (NYSE:SMR) | The SMR Pioneer with a Head Start NuScale Power holds a distinct advantage as the first U.S. company to secure Nuclear Regulatory Commission (NRC) approval for its small modular reactor (SMR) design—the 77-megawatt VOYGR module. But the company isn't resting on this milestone; it is rapidly advancing a 2-gigawatt agreement with Standard Power to supply data centers in Pennsylvania and Ohio. Despite posting losses as it invests in expanding its supply chain, NuScale's Q1 report revealed an impressive 857% year-over-year revenue increase. The recent Meta-Constellation Energy deal also boosted NuScale's stock, signaling strong market confidence in its role in nuclear's resurgence. What distinguishes NuScale from its competitors is its pragmatic approach. Its light-water reactor technology is more established and less experimental than Oklo's fast reactors, making it a safer candidate for near-term deployment. However, supply chain constraints and complex project coordination remain significant challenges that could delay progress. Still, with tech giants like Google and Amazon entering SMR agreements, NuScale's first-mover advantage positions it well to meet growing energy demands. Its factory-built, modular design aligns perfectly with data centers' requirements for scalable, reliable power. Is NuScale Power a Good Stock to Buy? NuScale Power is currently covered by eight Wall Street analysts, who generally hold a bullish outlook. The stock carries a Moderate Buy consensus rating, reflecting five Buy ratings, two Holds, and one Sell over the past three months. However, SMR's average price target of $27.42 suggests approximately 12% downside potential over the next twelve months. Why Nuclear Energy Is the Smart Bet for AI's Future The resurgence of the nuclear sector is no coincidence, as the soaring energy demands of AI are reshaping the industry landscape. Constellation Energy (CEG) brings scale, Oklo (OKLO) leads with innovation, and NuScale Power (SMR) holds a regulatory advantage. Each faces its own challenges—CEG's stock trades at a premium valuation, Oklo is still managing significant cash burn, and NuScale navigates operational risks. Nevertheless, the potential upside is substantial. With tech giants committing to multi-gigawatt agreements and nuclear capacity projected to quadruple by 2050, these companies are at the forefront of a transformative energy revolution and merit close attention.
Yahoo
an hour ago
- Yahoo
Why Greif Stock Triumphed on Thursday
The company published its second earnings release of the current fiscal year. This pleased investors largely because of a sizable earnings beat. 10 stocks we like better than Greif › Veteran industrial company Greif (NYSE: GEF) was a standout on the stock exchange Thursday. Investors, captivated by a very convincing earnings beat in the company's freshly reported second quarter of fiscal 2025, pushed the industrial packing specialist's share price up by nearly 16%. In doing so, Greif not only crushed the S&P 500 index's performance on the day (it landed in the red by 0.5%), but also that of many blue chip stocks. Greif published those quarterly results just after market close on Wednesday, divulging that its net sales inched up by 1% on a year-over-year basis to hit nearly $1.39 billion. The dynamic was similar on the bottom line, with GAAP net income bumping 0.5% higher to $54.5 million, or $1.22 per share. Although the consensus analyst estimate for revenue was higher, at $1.42 billion, pundits tracking the stock underestimated profitability. Collectively, they were anticipating Greif would only earn $1.12 per share in net income. In its earnings release, Greif management indicated a steady-as-she-goes approach to its business. It quoted CEO Ole Rosgaard as saying that "The resilience of our results, supported by deliberate portfolio moves and operational discipline, demonstrates that Greif is well-positioned for success and value creation now and in the future." Greif cautiously proffered selected guidance for the entirety of this fiscal year, raising the low end of its projection for non-GAAP (adjusted) earnings before interest, taxes, depreciation, and amortization (EBITDA) to $725 million and its adjusted free cash flow to $280 million. Both estimates compare positively to the actual fiscal 2024 results of $694 million and just under $190 million, respectively. Greif isn't the most exciting company on the scene, but at times, it's the unexciting businesses that produce the most dependably pleasing results. This one does what it does well, and what's more it knows how to keep its investors happy with a relatively high-yield dividend. I think it' s a fine stock to own, even after the post-earnings pop. Before you buy stock in Greif, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Greif wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,538!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $869,841!* Now, it's worth noting Stock Advisor's total average return is 789% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Greif Stock Triumphed on Thursday was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
